Related Experiment Video
Updated: Aug 13, 2026
Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays
Published on: April 4, 2011
Collaborative study to establish the first international standard for quantitation of anti-HPA-1a
Insights
A new freeze-dried standard for anti-human platelet antigen 1a (HPA-1a) immunoglobulin G (IgG) antibodies is available. This International Standard allows for reliable quantification of anti-HPA-1a activity in clinical samples.
Area of Science:
- Immunology
- Hematology
- Biotechnology
Background:
- Development of a freeze-dried preparation of pooled human plasma.
- The preparation contains immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a).
- Coded 03/152, it is proposed as an International Standard.
Purpose of the Study:
- To establish an International Standard for quantifying anti-HPA-1a activity.
- To provide a reference for quantitative assays in clinical settings.
- To facilitate accurate measurement of anti-HPA-1a in patient samples.
Main Methods:
- Pooling of plasma samples with potent anti-HPA-1a.
- Freeze-drying of plasma in 1-ml ampoules.
- Validation through an international collaborative study involving 39 laboratories.
Main Results:
- The proposed standard (03/152) contains 100 arbitrary units of anti-HPA-1a.
- An international study confirmed reliable determination of anti-HPA-1a activity in test samples.
- The standard was successfully used by laboratories in 24 countries.
Conclusions:
- The established standard enables laboratories to measure anti-HPA-1a activity in patient samples.
- Further research is needed to correlate anti-HPA-1a activity with clinical outcomes in neonatal alloimmune thrombocytopenia (NAIT).
Background And Objectives:
This report describes the production of a freeze-dried preparation of pooled human plasma, containing immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a). The material, coded 03/152, is proposed as an International Standard containing 100 arbitrary units of anti-HPA-1a for use in quantitative assays to determine the anti-HPA-1a activity in clinical samples.
Materials And Methods:
Plasma samples containing potent anti-HPA-1a were pooled and freeze dried in 1-ml ampoules. In addition, three individual plasma samples were selected which had varying levels of anti-HPA-1a activity. The anti-HPA-1a activity of these three samples was determined by using a variety of quantitative assays with the proposed standard as a reference.
Results:
An international collaborative study, which was part of the 2004 ISBT Platelet Immunology Workshop, involved 39 laboratories in 24 countries and showed that the anti-HPA-1a activity in three test samples could be reliably determined by using the proposed standard.
Conclusions:
Laboratories can use this standard to measure the anti-HPA-1a activity in patient's samples. Further studies are required to determine the relationship between anti-HPA-1a activity and clinical outcome in patients with neonatal alloimmune thrombocytopenia (NAIT).
